Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Feb;77(2):514–519. doi: 10.1172/JCI112331

Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin.

K Nanjo, T Sanke, M Miyano, K Okai, R Sowa, M Kondo, S Nishimura, K Iwo, K Miyamura, B D Given, et al.
PMCID: PMC423373  PMID: 3511099

Abstract

We have identified a non-insulin-dependent diabetic patient with fasting hyperinsulinemia (90 microU/ml), an elevated insulin:C-peptide molar ratio (1.68; normal, 0.05-0.20), normal insulin counterregulatory hormone levels, and an adequate response to exogenously administered insulin. Insulin-binding antibodies were absent from serum, erythrocyte insulin receptor binding was normal, and greater than 90% of circulating immunoreactive insulin coeluted with 125I-labeled insulin on gel filtration. The patient's insulin diluted in parallel with a human standard in the insulin radioimmunoassay, confirming close molecular similarity. The patient's insulin was purified from serum and shown to possess both reduced binding and ability to stimulate glucose uptake and oxidation in vitro. Analysis of the patient's insulin by high-performance liquid chromatography (HPLC) revealed two products: 7.3% of insulin immunoreactivity coeluted with the human standard, while the remaining 92.7% eluted as a single peak with increased hydrophobicity. Family studies confirmed the presence of hyperinsulinemia in four of five relatives in three generations, with secretion of an abnormal insulin documented by HPLC in the three tested. Leukocyte DNA was harvested from the propositus and the insulin gene cloned. One allele was normal, but the other displayed a thymine for guanine substitution at nucleotide position 1298 from the putative cap site, resulting in a leucine for valine substitution at position 3 of the insulin A chain. Insulin Wakayama is therefore identified as [LeuA3] insulin.

Full text

PDF
514

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell G. I., Karam J. H., Rutter W. J. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci U S A. 1981 Sep;78(9):5759–5763. doi: 10.1073/pnas.78.9.5759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blundell T. L., Cutfield J. F., Cutfield S. M., Dodson E. J., Dodson G. G., Hodgkin D. C., Mercola D. A. Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes. 1972;21(2 Suppl):492–505. doi: 10.2337/diab.21.2.s492. [DOI] [PubMed] [Google Scholar]
  3. De Meyts P., Van Obberghen E., Roth J. Mapping of the residues responsible for the negative cooperativity of the receptor-binding region of insulin. Nature. 1978 Jun 15;273(5663):504–509. doi: 10.1038/273504a0. [DOI] [PubMed] [Google Scholar]
  4. Faber O. K., Binder C., Markussen J., Heding L. G., Naithani V. K., Kuzuya H., Blix P., Horwitz D. L., Rubenstein A. H. Characterization of seven C-peptide antisera. Diabetes. 1978;27 (Suppl 1):170–177. doi: 10.2337/diab.27.1.s170. [DOI] [PubMed] [Google Scholar]
  5. Felig P., Wahren J., Hendler R. Influence of maturity-onset diabetes on splanchnic glucose balance after oral glucose ingestion. Diabetes. 1978 Feb;27(2):121–126. doi: 10.2337/diab.27.2.121. [DOI] [PubMed] [Google Scholar]
  6. Gabbay K. H., DeLuca K., Fisher J. N., Jr, Mako M. E., Rubenstein A. H. Familial hyperproinsulinemia. An autosomal dominant defect. N Engl J Med. 1976 Apr 22;294(17):911–915. doi: 10.1056/NEJM197604222941701. [DOI] [PubMed] [Google Scholar]
  7. Gambhir K. K., Archer J. A., Bradley C. J. Characteristics of human erythrocyte insulin receptors. Diabetes. 1978 Jul;27(7):701–708. doi: 10.2337/diab.27.7.701. [DOI] [PubMed] [Google Scholar]
  8. Given B. D., Mako M. E., Tager H. S., Baldwin D., Markese J., Rubenstein A. H., Olefsky J., Kobayashi M., Kolterman O., Poucher R. Diabetes due to secretion of an abnormal insulin. N Engl J Med. 1980 Jan 17;302(3):129–135. doi: 10.1056/NEJM198001173020301. [DOI] [PubMed] [Google Scholar]
  9. Glass A. R., Burman K. D., Dahms W. T., Boehm T. M. Endocrine function in human obesity. Metabolism. 1981 Jan;30(1):89–104. doi: 10.1016/0026-0495(81)90224-9. [DOI] [PubMed] [Google Scholar]
  10. Gliemann J., Sonne O., Linde S., Hansen B. Biological potency and binding affinity of monoiodoinsulin with iodine in tyrosine A14 or tyrosine A19. Biochem Biophys Res Commun. 1979 Apr 27;87(4):1183–1190. doi: 10.1016/s0006-291x(79)80032-7. [DOI] [PubMed] [Google Scholar]
  11. Goldman J., Baldwin D., Pugh W., Rubenstein A. H. Equilibrium binding assay and kinetic characterization of insulin antibodies. Diabetes. 1978 Jun;27(6):653–660. doi: 10.2337/diab.27.6.653. [DOI] [PubMed] [Google Scholar]
  12. Haneda M., Chan S. J., Kwok S. C., Rubenstein A. H., Steiner D. F. Studies on mutant human insulin genes: identification and sequence analysis of a gene encoding [SerB24]insulin. Proc Natl Acad Sci U S A. 1983 Oct;80(20):6366–6370. doi: 10.1073/pnas.80.20.6366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haneda M., Polonsky K. S., Bergenstal R. M., Jaspan J. B., Shoelson S. E., Blix P. M., Chan S. J., Kwok S. C., Wishner W. B., Zeidler A. Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome. N Engl J Med. 1984 May 17;310(20):1288–1294. doi: 10.1056/NEJM198405173102004. [DOI] [PubMed] [Google Scholar]
  14. Kuzuya T., Saito T., Yoshida S., Matsuda A. Human C-peptide immunoreactivity (CPR) in blood and urine - evaluation of a radioimmunoassay method and its clinical applications. Diabetologia. 1976 Oct;12(5):511–518. doi: 10.1007/BF01219516. [DOI] [PubMed] [Google Scholar]
  15. Kwok S. C., Chan S. J., Rubenstein A. H., Poucher R., Steiner D. F. Loss of a restriction endonuclease cleavage site in the gene of a structurally abnormal human insulin. Biochem Biophys Res Commun. 1981 Feb 12;98(3):844–849. doi: 10.1016/0006-291x(81)91188-8. [DOI] [PubMed] [Google Scholar]
  16. Kwok S. C., Steiner D. F., Rubenstein A. H., Tager H. S. Identification of a point mutation in the human insulin gene giving rise to a structurally abnormal insulin (insulin Chicago). Diabetes. 1983 Sep;32(9):872–875. doi: 10.2337/diab.32.9.872. [DOI] [PubMed] [Google Scholar]
  17. Murphy B. E. Some studies of the protein-binding of steroids and their application to the routine micro and ultramicro measurement of various steroids in body fluids by competitive protein-binding radioassay. J Clin Endocrinol Metab. 1967 Jul;27(7):973–990. doi: 10.1210/jcem-27-7-973. [DOI] [PubMed] [Google Scholar]
  18. Odell W. D., Rayford P. L., Ross G. T. Simplified, partially automated method for radioimmunoassay of human thyroid-stimulating, growth, luteinizing, and follicle stimulating hormones. J Lab Clin Med. 1967 Dec;70(6):973–980. [PubMed] [Google Scholar]
  19. Olefsky J. M. Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest. 1975 Dec;56(6):1499–1508. doi: 10.1172/JCI108231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pullen R. A., Lindsay D. G., Wood S. P., Tickle I. J., Blundell T. L., Wollmer A., Krail G., Brandenburg D., Zahn H., Gliemann J. Receptor-binding region of insulin. Nature. 1976 Feb 5;259(5542):369–373. doi: 10.1038/259369a0. [DOI] [PubMed] [Google Scholar]
  21. RODBELL M. METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. J Biol Chem. 1964 Feb;239:375–380. [PubMed] [Google Scholar]
  22. Reaven G. M., Bernstein R., Davis B., Olefsky J. M. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med. 1976 Jan;60(1):80–88. doi: 10.1016/0002-9343(76)90536-2. [DOI] [PubMed] [Google Scholar]
  23. Robbins D. C., Blix P. M., Rubenstein A. H., Kanazawa Y., Kosaka K., Tager H. S. A human proinsulin variant at arginine 65. Nature. 1981 Jun 25;291(5817):679–681. doi: 10.1038/291679a0. [DOI] [PubMed] [Google Scholar]
  24. Robbins D. C., Tager H. S., Rubenstein A. H. Biologic and clinical importance of proinsulin. N Engl J Med. 1984 May 3;310(18):1165–1175. doi: 10.1056/NEJM198405033101807. [DOI] [PubMed] [Google Scholar]
  25. Scarlett J. A., Gray R. S., Griffin J., Olefsky J. M., Kolterman O. G. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982 Jul-Aug;5(4):353–363. doi: 10.2337/diacare.5.4.353. [DOI] [PubMed] [Google Scholar]
  26. Seed B. Purification of genomic sequences from bacteriophage libraries by recombination and selection in vivo. Nucleic Acids Res. 1983 Apr 25;11(8):2427–2445. doi: 10.1093/nar/11.8.2427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Seino S., Funakoshi A., Fu Z. Z., Vinik A. Identification of insulin variants in patients with hyperinsulinemia by reversed-phase, high-performance liquid chromatography. Diabetes. 1985 Jan;34(1):1–7. doi: 10.2337/diab.34.1.1. [DOI] [PubMed] [Google Scholar]
  28. Shoelson S. E., Polonsky K. S., Zeidler A., Rubenstein A. H., Tager H. S. Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model. J Clin Invest. 1984 May;73(5):1351–1358. doi: 10.1172/JCI111338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shoelson S., Fickova M., Haneda M., Nahum A., Musso G., Kaiser E. T., Rubenstein A. H., Tager H. Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7390–7394. doi: 10.1073/pnas.80.24.7390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shoelson S., Haneda M., Blix P., Nanjo A., Sanke T., Inouye K., Steiner D., Rubenstein A., Tager H. Three mutant insulins in man. Nature. 1983 Apr 7;302(5908):540–543. doi: 10.1038/302540a0. [DOI] [PubMed] [Google Scholar]
  31. Tager H., Given B., Baldwin D., Mako M., Markese J., Rubenstein A., Olefsky J., Kobayashi M., Kolterman O., Poucher R. A structurally abnormal insulin causing human diabetes. Nature. 1979 Sep 13;281(5727):122–125. doi: 10.1038/281122a0. [DOI] [PubMed] [Google Scholar]
  32. Ueda Y. [Specificity of insulin action on fat cell of the Zucker genetically obese rat "fatty". [II]. "Insulin binding on fat cell and the biological activity of bound inslulin" (author's transl)]. Nihon Naibunpi Gakkai Zasshi. 1977 May 20;53(5):679–689. doi: 10.1507/endocrine1927.53.5_679. [DOI] [PubMed] [Google Scholar]
  33. Zahn H., Brandenburg D., Gattner H. G. Molecular basis of insulin action: contributions of chemical modifications and synthetic approaches. Diabetes. 1972;21(2 Suppl):468–475. doi: 10.2337/diab.21.2.s468. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES